Comparing QL2107 with Keytruda after lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, QL2107, against Keytruda, a standard treatment, for people with stage II or IIIA non-small cell lung cancer that has been completely removed by surgery. The goal is to see if QL2107 works as well as Keytruda in preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had surgery to remove all visible non-small cell lung cancer (stage II or IIIA).
- You received chemotherapy after surgery, starting within 12 weeks of surgery, and your last chemo dose was at least 3 weeks ago but no more than 12 weeks before starting the trial.
- You have no signs of cancer remaining after surgery, as confirmed by scans.
- You are physically able to carry out daily activities (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new medicine (HLX17) against a standard immunotherapy drug (Keytruda) as a first treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if the new medicine works just as well and is safe.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.